Statement: 1 patient in the primary trial had toxic hepatitis.
Primary_evidence: Adverse Events 1:   Total: 30/112 (26.79%)   Thrombocytopenia 1/112 (0.89%)   Dysphagia 1/112 (0.89%)   Haemorrhoidal haemorrhage 1/112 (0.89%)   Oesophageal stenosis 1/112 (0.89%)   Upper gastrointestinal haemorrhage 1/112 (0.89%)   Asthenia 1/112 (0.89%)   Disease progression 1/112 (0.89%)   Hepatotoxicity 1/112 (0.89%)   Cellulitis 3/112 (2.68%)   Pneumonia 2/112 (1.79%)   Osteomyelitis 1/112 (0.89%)